Canaccord Genuity Group Reiterates “Buy” Rating for CeriBell (NASDAQ:CBLL)

Canaccord Genuity Group restated their buy rating on shares of CeriBell (NASDAQ:CBLL) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $33.00 price objective on the stock.

Several other equities analysts have also recently issued reports on the company. TD Cowen boosted their target price on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Bank of America assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target on the stock. William Blair initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. Finally, Canaccord Genuity Group began coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $32.60.

CeriBell Stock Down 1.3 %

Shares of NASDAQ CBLL opened at $25.20 on Wednesday. The stock’s 50-day simple moving average is $23.40. CeriBell has a 12 month low of $18.69 and a 12 month high of $32.75.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. Sell-side analysts anticipate that CeriBell will post -2.46 EPS for the current year.

Institutional Investors Weigh In On CeriBell

Hedge funds have recently bought and sold shares of the business. Legal & General Group Plc purchased a new position in shares of CeriBell during the fourth quarter valued at approximately $32,000. Summit Investment Advisors Inc. bought a new stake in CeriBell in the fourth quarter worth $33,000. Tower Research Capital LLC TRC purchased a new stake in shares of CeriBell in the fourth quarter worth $37,000. BNP Paribas Financial Markets bought a new position in shares of CeriBell during the fourth quarter valued at $43,000. Finally, PNC Financial Services Group Inc. purchased a new position in shares of CeriBell in the 4th quarter worth about $47,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.